Invokana Lawsuit Attorneys at Bernstein Liebhard LLP Note FDA Action on Kidney Risks Associated with Invokana, Other Diabetes Drugs

June 15, 2016 (PRLEAP.COM) Business News
June 15, 2016 - The Invokana lawsuit ( attorneys at Bernstein Liebhard LLP report that U.S. health regulators have ordered stronger warnings regarding the kidney complications potentially associated with the use of certain Type 2 diabetes medications, including Invokana, Invokamet, Farxiga and Xigduo XR. According to a Drug Safety Communication issued by the U.S. Food & Drug Administration (FDA) on June 14th, existing warnings will be modified to include information about acute kidney injury and recommendations to minimize risk.

The FDA disclosed that its adverse event database logged 101 reports of acute kidney injury related to Invokana/Invokamet (canagliflozin) and Farxiga/Xigduo XR (dapagliflozin) between March 2013 and October 2015. In some of the cases, patients required hospitalization and dialysis. The agency advised health care providers to assess a patient's kidney function before prescribing any of these drugs and to monitor kidney function during treatment. They should also consider factors that may predispose patients to acute kidney injury prior to initiating treatment. The medications should be stopped in patients with acute kidney injury, and the kidney impairment should be treated.

"Our Firm has been investigating the complications potentially associated with Invokana, and have heard from a number of patients who allegedly suffered kidney problems while using the medication. We are pleased that the FDA has taken steps to better inform patients and doctors of this risk," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating product liability claims on behalf of Type 2 diabetes patients who were allegedly injured as result of Invokana or similar medications.

Invokana Side Effects
Invokana, Invokamet, Farxiga and Xigduo XR belong to a class of Type 2 diabetes medications called sodium-glucose cotransporter-2 (SGLT2) inhibitors. These drugs work by preventing the reabsorption of glucose by the kidneys, thereby facilitating its removal from the body via urine. Other drugs in this class include Jardiance, and Glyxambi.

In May 2015, the FDA revealed that it was investigating reports linking Invokana, Invokamet and other SGLT2 inhibitors to a potentially life-threatening condition called diabetic ketoacidosis, which occurs when toxic acids called ketones accumulate in the blood stream. In December, the agency announced that information regarding this potential complication would be added to the "Warnings and Precautions" section on all SGLT2 inhibitors labels. The labels were also modified with information about life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that originate as urinary tract infections.

In September 2015, the FDA announced that the labels for Invokana and Invokamet would be updated to include information about a possible increased risk of bone fractures, after several clinical trials confirmed that fractures were more likely among patients exposed to canagliflozin. And just last month, the agency disclosed that it was investigating a possible link between the use of canagliflozin and an increased incidence of leg and foot amputations, mostly affecting the toes.

Bernstein Liebhard LLP is investigating legal claims on behalf of Type 2 diabetics who developed diabetic ketoacidosis or kidney complications allegedly related to the use of Invokana, Invokamet or another SGLT2 inhibitor. To learn more about filing an Invokana lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share Article